Proteomic and Genetic Biomarkers for Early Detection of Ovarian Cancer
Researchers use layer hens, which naturally develop ovarian cancer like humans, to identify a 25-protein/gene biomarker panel from blood samples, enabling earlier and more accurate detection of human ovarian cancer.
Background
Ovarian cancer is the second leading cause of gynecologic cancer-related death worldwide. Because early-stage ovarian cancer is usually asymptomatic, the cancer progresses and spreads undiagnosed, leading to a high fatality rate. There is a critical need within the medical community for effective early detection methodologies. Identifying the disease in its early stages is essential to significantly reducing the overall disease burden, improving patient prognoses, and ultimately increasing long-term survival rates. Current diagnostic approaches are severely limited by tumor molecular heterogeneity and a reliance on standard laboratory mouse models, which fail to develop the spontaneous ovarian cancer required to accurately mimic human disease progression, staging, and early biomarker discovery.
Technology
To address this challenge, University of Delaware Researchers have developed a 25-biomarker panel of proteins and genes designed specifically for the early detection of ovarian cancer. Developed through a cross-species analytical approach, the technology leverages layer hens, an animal model that naturally develops spontaneous ovarian cancer closely mirroring human disease progression and molecular heterogeneity. By combining longitudinal plasma sampling with advanced proteomic and genomic identification, this panel translates disease onset findings directly into human applications, enabling early clinical intervention before late-stage complications arise.
Benefits
-
Early Detection: Enables the diagnosis of ovarian cancer in early stages of progression when treatment options are better and long-term mortality rates are improved.
-
Minimally Invasive: Facilitates patient-friendly testing via standard plasma sampling.
-
High Diagnostic Accuracy: Addresses complex molecular tumor heterogeneity using a comprehensive 25-biomarker panel and accurately detects ovarian cancer.
Applications
-
Early-Stage Routine Screening Tests:
-
Hereditary Companion Diagnostics
-
Clinical Trial Patient Stratification
-
Longitudinal Therapeutic Tracking Platforms
-
Oncology Research Assay Kits
Additional info
This diagnostic platform comprises a 25-protein/gene biomarker panel for early-stage human ovarian cancer detection. Developed via longitudinal plasma sampling and cross-species proteomic and genomic profiling using spontaneous layer-hen disease models and human samples, the assay resolves molecular heterogeneity to identify pre-symptomatic disease onset, mitigating late-stage mortality and reducing clinical disease burden.